Immutep will conduct a new Phase IIb clinical trial in 1st line
HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.
Immutep maintains control of trial, very important in my mind for any commercial discussions which
may take place in the future.......Merck increasing supply agreement, presumably with more interest...
Immutep will conduct a new Phase IIb clinical trial in 1st...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |